Clinical Trial Update: NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC [Phase 1]

View source ↗

Summary

This document provides a Phase 1 clinical trial update for TAEST16001 NY-ESO-1–targeted T-cell receptor therapy in patients with advanced non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAEST16001 NY-ESO-1 TCR (NY-ESO-1–specific T-cell receptor)

Snippet

Sponsor: Guangzhou Institute of Respiratory Disease | Conditions: Lung Cancer, Nonsmall Cell, Recurrent | Phase 1 | Status: UNKNOWN